Renal Artery Stenosis

Researchers are evaluating a preventive, multidisciplinary primary care intervention designed around a therapeutic garden to assess its acceptability among patients with cardio-neurovascular diseases. This study focuses on individuals suffering from various vascular conditions, including atrial fibrillation, heart failure NYHA Class II, cardiomyopathies, ischemic stroke, and resistant hypertension. The main goal is to understand how patients and those involved in their care respond to this novel intervention. The intervention consists of a 6-month program that includes gardening activities, adapted physical exercise, nutritional workshops, and questionnaires to gather feedback. Participants may either take part in this multidisciplinary preventive action or choose not to receive the intervention but still complete questionnaires explaining their reasons. The study compares these two groups to identify acceptance rates and factors influencing participation. Participants will be involved for six months, during which their acceptance of the intervention and any obstacles or facilitators will be recorded. Researchers will assess the impact of the program through questionnaires and follow-up evaluations. The study monitors participants from enrollment through the end of treatment, aiming to gather comprehensive data on the interventions feasibility and effects on patients with cardio-neurovascular conditions.

Researchers are conducting a prospective national registry in Denmark to observe and collect data on percutaneous transluminal renal angioplasty PTRA in patients who have high-risk renovascular hypertension. This registry includes patients selected based on common national criteria and follows a standardized protocol across three Danish centers offering PTRA. The study aims to evaluate changes in blood pressure and other health outcomes after the procedure. The intervention being studied is percutaneous transluminal renal angioplasty, including angioplasty with stenting, especially in patients with fibromuscular dysplasia. Additional treatments such as antiplatelet therapy, cholesterol-lowering drugs, antihypertensive medications, and lifestyle measures like smoking cessation, diet, and physical activity are used according to the physicians discretion. The study monitors patients over time following their PTRA treatment. Participants undergo regular assessments including 24-hour ambulatory blood pressure monitoring and kidney function tests. The primary outcome measured is the change in systolic and diastolic blood pressures 24 months after PTRA in patients with elevated baseline blood pressure. Secondary outcomes include blood pressure changes at multiple time points, adjustments in antihypertensive treatment, kidney function changes, clinical and safety endpoints. Follow-up evaluations occur up to 60 months post-treatment to monitor long-term effects and safety.

Researchers are evaluating the long-term safety and effectiveness of the NOVA intracranial drug-eluting stent system in patients with intracranial atherosclerotic stenosis. This study is a prospective, multi-center, single-arm clinical trial conducted across about 50 centers in China, aiming to include 1000 participants who are suitable candidates for stent angioplasty. The trial will run from December 2022 to December 2030, focusing on patients with significant artery narrowing in the brain. All participants will receive the NOVA drug-eluting stent, which is designed to treat intracranial artery stenosis with a sirolimus-eluting coating and a rapid exchangeable balloon. The study includes ten visits starting from preoperative screening, the operation day, then follow-ups at 30 days, 3 months, 6 months, 1 year, and annually up to 5 years after the procedure. This schedule allows researchers to closely monitor the devices performance and patient outcomes over time. Participants will undergo various assessments during these visits, including evaluations for stroke, death, ischemic events, and revascularization related to the treated artery. Other measures include rates of stroke in different brain regions, transient ischemic attacks, restenosis, bleeding events, and quality of life assessments using tools like the modified Rankin Scale and EuroQol-5D. Safety, device defects, and long-term outcomes will be carefully tracked throughout the study period, which lasts up to five years after the operation.

This research aims to evaluate how people with Spontaneous Coronary Artery Dissection SCAD andor Fibromuscular Dysplasia FMD respond in terms of heart and lung function, blood flow, and symptoms during different types and intensities of exercise. The study focuses on these specific conditions and seeks to understand the effects of aerobic and resistance exercises on affected individuals. Participants will complete three exercise tests separated by at least 48 hours. These include a symptom-limited cardiopulmonary exercise test involving cycling with increasing effort to exhaustion, a two-stage submaximal cycling test with moderate and heavy intensity phases, and a series of six resistance exercises such as chest press, lateral raises, abdominal crunches, planks, leg press, and weighted lunges. Each test is designed to measure responses under controlled exercise conditions. During the study, participants will have their blood pressure, perceived exertion, and blood lactate levels measured at various time points before, during, and after exercise. Questionnaires assessing functional status and physical activity will also be completed at baseline. The study monitors these outcomes to understand exercise impact and safety in this population. Participation will last through these testing periods with assessments occurring around the exercise sessions.

Researchers are investigating how minocycline affects blood pressure in adults with treatment-resistant hypertension. The study aims to determine to what degree minocycline lowers blood pressure and whether these effects involve changes in the gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or a combination of these factors. This phase 4 clinical trial includes a neuroimaging substudy to explore brain-related impacts. Participants will be randomly assigned to receive either minocycline hydrochloride 100 mg twice daily or a matching placebo, both given for 3 months. The study includes three visits screening, randomization, and a 3-month follow-up. Those in the neuroimaging substudy will undergo PETMR imaging at each visit. Throughout the study, participants will undergo medical exams, behavioral questionnaires, blood tests for various biomarkers, urine and saliva tests to assess adherence, stool sample analysis for gut microbiota, and blood pressure monitoring including unattended office and 24-hour ambulatory measurements. At the final visit, blood will also be tested for drug concentration to confirm treatment adherence. The main outcomes measured include 24-hour systolic blood pressure, gut microbiome changes, gut inflammation and leakiness, and neuroinflammation.

This observational study is designed to assess kidney blood flow in adults undergoing planned minimally invasive abdominal surgery. It focuses on evaluating how renal perfusion changes during and after surgery using two non-invasive methods Doppler ultrasonography-derived Renal Resistive Index RRI and Near-Infrared Spectroscopy NIRS-derived regional renal oxygen saturation rSO2. The study aims to understand the effects of surgery-related factors on kidney function and the possible development of acute kidney injury. Participants will have kidney blood flow measurements taken at specific times after anesthesia induction, during the creation of pneumoperitoneum, just before removing the breathing tube, and one hour after extubation. These measurements will be correlated with clinical data such as intra-abdominal pressure, surgery duration, fluid intake, urine output, and postoperative kidney function. The study will gather detailed patient information including demographics, comorbidities, and intraoperative variables. Throughout the study, researchers will monitor perioperative kidney blood flow and evaluate its relationship with postoperative outcomes like acute kidney injury. The data collection includes ultrasound and NIRS assessments, clinical and laboratory tests, fluid balance, and ventilatory parameters. This will help to improve understanding of kidney perfusion changes during minimally invasive surgery and may guide better kidney protection strategies in the future.

Researchers are evaluating the baroloop system, a device implanted to stimulate the vagus nerve, for treating adults with hypertension that does not respond well to medication. The study aims to find out if the baroloop is safe, including checking for serious medical problems or death, and if it effectively lowers blood pressure in participants. This is a multicenter clinical trial sponsored by neuroloop GmbH. Participants will have the baroloop device implanted and will attend follow-up visits at 14 days, 3 months, 6 months, 12 months, 18 months, and 24 months after implantation. During these visits, device settings may be adjusted, and various assessments related to the study will be performed. Participants will also answer questions about their quality of life throughout the study period. During the trial, researchers will monitor safety and performance outcomes, especially focusing on safety and blood pressure changes 6 months after stimulation begins. Participants will undergo regular clinical evaluations and provide feedback on their well-being. The total duration of participation includes multiple visits over two years, ensuring close monitoring and adjustment of the device as needed.

Researchers are conducting a large, international observational study called the Canadian SCAD Study to understand spontaneous coronary artery dissection SCAD, a condition that mainly affects young women without usual heart risk factors and can lead to heart attacks or death. SCAD is often misdiagnosed due to limits of current tests, so this study aims to better understand the conditions natural history, predisposing factors, and treatments over time. The study will enroll about 3,000 patients diagnosed with SCAD from multiple centers in Canada, the United States, and other countries. Participants will be followed for up to 10 years to track cardiovascular events. A genetic sub-study involves a one-time saliva sample collection. The study uses electronic consent for wide geographic participation and collects detailed health history and investigations related to SCAD. Participants will undergo detailed baseline assessments, including history and diagnostic testing, and will be monitored regularly for heart-related outcomes both during hospitalization and over the long term. The main outcomes measured include cardiovascular events during hospital stay and up to 10 years later. Secondary outcomes include arterial healing and success of coronary procedures. This long-term follow-up aims to improve knowledge of SCAD and guide future treatment trials.

Researchers are studying patients with atherosclerotic carotid stenosis, including both symptomatic patients with stenosis over 50% and asymptomatic patients with stenosis 80% or greater. This trial compares early neurological outcomes using two different embolic protection devices combined with the CGuard microNet covered stent. The purpose is to evaluate whether distal or proximal embolic protection device placement offers better results, expanding on previous findings that showed CGuard stent implantation had advantages over classical stents using distal protection. Participants will undergo carotid artery stenting with one of two devices the Emboshield NAV6 distal embolic protection system plus the CGuard stent, or the Mo.Ma proximal cerebral protection device plus the CGuard stent. The study groups are randomized and unblinded, and both devices aim to reduce embolic events during the stenting procedure. The trial began in November 2021 and will continue until January 2027. During the study, participants will receive neurological assessments and brain imaging to detect ischemic lesions within 24 to 48 hours after the procedure. The primary outcome is the determination of these ischemic lesions, while secondary outcomes include monitoring major adverse cardiac and cerebrovascular events during and shortly after the procedure. Participants must consent to follow-up visits and procedures as part of the trial involvement.

Researchers are investigating the relationship between blood pressure changes and catecholamine levels in the adrenal venous and peripheral venous blood of patients with primary aldosteronism PA who have high blood pressure and undergo percutaneous selective adrenal artery embolization SAAE. This study aims to understand why some patients experience large blood pressure spikes during SAAE while others do not, and to explore the possible mechanisms behind these blood pressure fluctuations caused by the treatment. The study involves collecting blood samples from two groups one from the adrenal vein and another from the peripheral vein in patients with PA undergoing SAAE. This minimally invasive procedure blocks blood flow to the affected adrenal gland to reduce excess aldosterone production. Blood pressure and hormone levels including norepinephrine, adrenaline, dopamine, renin, aldosterone, sodium, and potassium will be measured immediately and at intervals up to 30 minutes after embolization. The study will capture detailed blood pressure readings before and after the procedure using invasive and 24-hour monitoring. Participants will be monitored closely during the procedure with multiple blood and blood pressure measurements taken at specific times. Researchers will analyze changes in blood pressure and hormone levels to better understand the physiological effects of SAAE. The study is observational, following patients who meet strict diagnostic and blood pressure criteria for PA. Participants will provide informed consent and be observed until the study concludes at the end of 2026. The findings aim to improve knowledge about blood pressure control during this minimally invasive treatment for PA.